# Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

> **NCT01649258** · PHASE1 · TERMINATED · sponsor: **University of Southern California** · enrollment: 29 (actual)

## Conditions studied

- Breast Cancer
- Nausea
- Vomiting

## Interventions

- **DRUG:** granisetron transdermal system
- **DRUG:** fosaprepitant dimeglumine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01649258
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-04
- **Primary completion:** 2017-05-22
- **Final completion:** 2017-09-30
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649258, "Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01649258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*